Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 4/20 | 0.63 |
| ▸ | ROCK1 known ✓ | Q13464 | 4/20 | 0.63 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.62 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.60 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.60 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 0.60 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 0.60 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.60 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.60 |
| ▸ | CHUK | O15111 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578926 | 0.98 | PTPN1 (0.69) | PTPN1HPGDROCK2ROCK1PKN2 | |
| Hydrochloric Acid SCHEMBL27545321 | 0.91 | ROCK2 (0.73) | PTPN1HPGDROCK2ROCK1PKN2 | |
| SCHEMBL30828553 | 0.89 | ROCK2 (0.76) | PTPN1HPGDROCK2ROCK1PKN2 | |
| SCHEMBL7520976 | 0.89 | ROCK2 (0.76) | PTPN1HPGDROCK2ROCK1PKN2 | |
| SCHEMBL28656982 | 0.85 | PTPN1 (0.89) | PTPN1HPGDLMNAPTPN2NAMPT | |
| SCHEMBL125695 | 0.85 | PTPN1 (0.89) | PTPN1HPGDLMNAPTPN2NAMPT | |
| SCHEMBL7327230 | 0.84 | EPHX1 (0.56) | PTPN1HPGDROCK2ROCK1PKN2 | |
| Hydrochloric Acid SCHEMBL27414471 | 0.83 | ROCK2 (0.60) | PTPN1ROCK2ROCK1PKN2TP53 | |
| SCHEMBL30828597 | 0.83 | ACVRL1 (0.72) | PTPN1ROCK2ROCK1PKN2TP53 | |
| SCHEMBL2105849 | 0.83 | ROCK2 (0.63) | PTPN1HPGDROCK2ROCK1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000735-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250236844-A1 | STEM CELL DERIVED ISLET DIFFERENTIATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-24 | — | — | US | disclosed |
| US-12215355-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240425817-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-26 | — | — | US | disclosed |
| US-11999971-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240093144-A1 | DIFFERENTIAL ADHESION AND TENSION GUIDED FORMATION OF STEM CELL DERIVED EMBRYOS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2024-03-21 | — | — | US | disclosed |
| EP-4271399-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230085395-A1 | STEM CELL DERIVED ISLET DIFFERENTIATION | VERTEX PHARMACEUTICALS INCORPORATED | 2023-03-16 | — | — | US | disclosed |
| US-20230075375-A1 | STEM CELL DERIVED ISLET DIFFERENTIATION | VERTEX PHARMACEUTICALS INCORPORATED | 2023-03-09 | — | — | US | disclosed |
| US-11525120-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-13 | — | — | US | disclosed |
| US-11466256-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220233646-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-07-28 | — | — | US | disclosed |
| WO-2022147056-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-3990624-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000735-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | IAPP, PNLIP, PPARD | ROCK2 3901/4885ROCK1 3753/4885PRKCE 215/4885 |
| US-20240425817-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | IAPP, AMY2A, CEL | ROCK2 4590/4885ROCK1 4712/4885PRKCE 1436/4885 |
| US-20220233646-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | IAPP, AMY2A, RNASE1 | ROCK2 4496/4885ROCK1 4716/4885PRKCE 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.